

CITATION REPORT

List of articles citing

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US

DOI: 10.1001/jamanetworkopen.2020.16144
JAMA Network Open, 2020, 3, e2016144.

Source: <https://exaly.com/paper-pdf/76551096/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
21	Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective. <i>Journal of Medical Economics</i> , 2021 , 24, 291-298	2.4	1
20	The nivolumab/cabozantinib combination and the future of doublets in advanced renal cell cancer treatment. <i>Journal of Oncology Pharmacy Practice</i> , 2021 , 27, 1553-1554	1.7	
19	Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. <i>Gynecologic Oncology</i> , 2021 , 162, 249-255	4.9	6
18	A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 370-370.e7	3.3	3
17	Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies. <i>Frontiers in Pharmacology</i> , 2021 , 12, 718014	5.6	1
16	Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 664-677	2.8	3
15	CheckMate-067: Raising the Bar for the Next Decade in Oncology. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102549	2.2	2
14	Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression $\geq 50\%$. <i>Frontiers in Pharmacology</i> , 2021 , 12, 803626	5.6	
13	A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022 , 45,	2.7	0
12	Recent Advances in First-Line Management of Metastatic Renal Cell Carcinoma. <i>Indian Journal of Medical and Paediatric Oncology</i> ,	0.2	
11	Immune Checkpoint Receptors Signaling in T Cells.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
10	First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 788569	5.6	1
9	Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 736860	5.6	0
8	Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA. <i>Clinical Drug Investigation</i> ,	3.2	0
7	The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. 13,		0
6	Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China. 10,		1
5	Chemotherapeutic Protocols for the Treatment of Genitourinary Cancer. 2022 , 201-231		0

- 4 Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. ○
- 3 The role of cytoreductive nephrectomy in the immuno-oncological therapy era. Publish Ahead of Print, ○
- 2 Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma. **2023**, ○
- 1 Health-related Quality of Life and Cost Effectiveness of Treatment: Components to Be Included in Clinical Decision-making. **2023**, ○